ProShare Advisors
MREO

ProShare Advisors’s Mereo BioPharma MREO Stock Holding History

ProShare Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,056
Closed -$14K – 1999
2022
Q1 		$14K Sell
12,056
-3,590
-23% -$4.64K ﹤0.01% 2191
2021
Q4 		$25K Buy
+15,646
New +$31.3K ﹤0.01% 2323

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ProShare Advisors's MREO Position: Q2 2022 in Review

ProShare Advisors sold out of Mereo BioPharma (MREO) in Q2 2022, closing a stake of 12,056 shares — an estimated $14K sold.

ProShare Advisors first reported a position in MREO in Q4 2021 and held it in 2 quarters. The position peaked at $25K in Q4 2021. 64 funds tracked by Wall St. Rank hold MREO as of Q2 2022.

  • ProShare Advisors reported no remaining Mereo BioPharma position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 12,056 Mereo BioPharma shares in Q2 2022, an estimated $14K.
  • ProShare Advisors first reported a position in Mereo BioPharma in Q4 2021 and held it in 2 quarters.
  • ProShare Advisors's Mereo BioPharma position peaked at $25K in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.